EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Polygenic Risk Score Is Associated with Developing and Dying from Lung Cancer in the National Lung Screening Trial

Robert P Young, Raewyn J Scott, Tom Callender, Fenghai Duan, Paul Billings, Denise R Aberle, Greg D Gamble iD

Journal of Clinical Medicine · 30.04.2025 · 14 (9) · 3110

DOI: 10.3390/jcm14093110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 30.04.2025. Verfasst von Robert P Young und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medical and Health Sciences, University of Auckland, Auckland P.O. Box 37-971, New Zealand. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was funded by a grant from Johnson and Johnson (no grant number), and grants U01-CA-80098 and U01-CA-79778 to the American College of Radiology Imag…, Johnson and Johnson, American College of Radiology Imaging Network (ACRIN).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Epidemiological studies suggest lung cancer results from the combined effects of smoking and genetic susceptibility. The clinical application of polygenic risk scores (PRSs), derived from combining the results from multiple germline genetic variants, have not yet been explored in a lung cancer screening cohort.

Methods

This was a post hoc analysis of 9191 non-Hispanic white subjects from the National Lung Screening Trial (NLST), a sub-study of high-risk smokers randomised to annual computed tomography (CT) or chest X-ray (CXR) and followed for 6.4 years (mean). This study’s primary aim was to examine the relationship between a composite polygenic risk score (PRS) calculated from 12 validated risk genotypes and developing or dying from lung cancer during screening. Validation was undertaken in the UK Biobank of unscreened ever-smokers (N = 167,796) followed for 10 years (median).

Results

In this prospective study, we found our PRS correlated with lung cancer incidence (p < 0.0001) and mortality (p = 0.004). In an adjusted multivariable logistic regression analysis, PRS was independently associated with lung cancer death (p = 0.0027). Screening participants with intermediate and high PRS scores had a higher lung cancer mortality, relative to those with a low PRS score (rate ratios = 1.73 (95%CI 1.14–2.64, p = 0.010) and 1.89 (95%CI 1.28–2.78, p = 0.009), respectively). This was despite comparable baseline demographics (including lung function) and comparable lung cancer characteristics. The PRS’s association with lung cancer mortality was validated in an unscreened cohort from the UK Biobank (p = 0.002).

Conclusions

In this biomarker-based cohort study, an elevated PRS was independently associated with dying from lung cancer in both screening and non-screening cohorts.

Schlagwörter

Stichwörter der Autor:innen

lung canceroutcomespolygenic risk scorescreening

Autor:innen und Institutionen

  • Faculty of Medical and Health Sciences, University of Auckland, Auckland P.O. Box 37-971, New Zealand.
  • Respiratory Research Group, Greenlane Clinical Centre, Epsom, Auckland 1344, New Zealand.
  • Department of Applied Health Research, University College London, London WC1E6B1, UK.
  • Department of Biostatistics and Centre for Biostatistics and Health Data Science, Brown University of Public Health, Providence, RI 02912, USA.
  • Natera Inc., Austin, TX 78753, USA.
  • Department of Radiological Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA.

ORCID-Profile: Greg D Gamble

Förderung

  • This study was funded by a grant from Johnson and Johnson (no grant number), and grants U01-CA-80098 and U01-CA-79778 to the American College of Radiology Imag…
  • Johnson and Johnson
  • American College of Radiology Imaging Network (ACRIN)

Zitieren

APA

Young, R. P., Scott, R. J., Callender, T., Duan, F., Billings, P., Aberle, D. R., & Gamble, G. D. (2025). Polygenic Risk Score Is Associated with Developing and Dying from Lung Cancer in the National Lung Screening Trial. Journal of Clinical Medicine, 14(9), 3110. https://doi.org/10.3390/jcm14093110

Vancouver

Young RP, Scott RJ, Callender T, Duan F, Billings P, Aberle DR, et al. Polygenic Risk Score Is Associated with Developing and Dying from Lung Cancer in the National Lung Screening Trial. Journal of Clinical Medicine. 2025;14(9):3110. doi:10.3390/jcm14093110

BibTeX
@article{Young2025,
  author = {Young, Robert P and Scott, Raewyn J and Callender, Tom and Duan, Fenghai and Billings, Paul and Aberle, Denise R and Gamble, Greg D},
  title = {Polygenic Risk Score Is Associated with Developing and Dying from Lung Cancer in the National Lung Screening Trial},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {9},
  pages = {3110},
  doi = {10.3390/jcm14093110}
}
Kostenlos starten →